Moseley, A., Freidlin, B., Shallis, R. M., Zeidan, A. M., Sallman, D. A., Little, R. F., … Othus, M. (2022). How Many Stratification Factors Are Reasonable and Can There be Too Many? Evaluation of Analysis Strategies in the Context of a Randomized Phase 2 Trial in Acute Myeloid Leukemia within the Myelomatch Platform. In Blood (Vol. 140, pp. 8932–8933). American Society of Hematology. https://doi.org/10.1182/blood-2022-170376

Moseley, Anna, Boris Freidlin, Rory Michael Shallis, Amer M. Zeidan, David A. Sallman, Richard F. Little, Harry P. Erba, Michael L. Leblanc, and Megan Othus. “How Many Stratification Factors Are Reasonable and Can There be Too Many? Evaluation of Analysis Strategies in the Context of a Randomized Phase 2 Trial in Acute Myeloid Leukemia within the Myelomatch Platform.” In Blood, 140:8932–33. American Society of Hematology, 2022. https://doi.org/10.1182/blood-2022-170376.

Moseley A, Freidlin B, Shallis RM, Zeidan AM, Sallman DA, Little RF, et al. How Many Stratification Factors Are Reasonable and Can There be Too Many? Evaluation of Analysis Strategies in the Context of a Randomized Phase 2 Trial in Acute Myeloid Leukemia within the Myelomatch Platform. In: Blood. American Society of Hematology; 2022. p. 8932–3.

Moseley, Anna, et al. “How Many Stratification Factors Are Reasonable and Can There be Too Many? Evaluation of Analysis Strategies in the Context of a Randomized Phase 2 Trial in Acute Myeloid Leukemia within the Myelomatch Platform.” Blood, vol. 140, no. Supplement 1, American Society of Hematology, 2022, pp. 8932–33. Crossref, doi:10.1182/blood-2022-170376.

Moseley A, Freidlin B, Shallis RM, Zeidan AM, Sallman DA, Little RF, Erba HP, Leblanc ML, Othus M. How Many Stratification Factors Are Reasonable and Can There be Too Many? Evaluation of Analysis Strategies in the Context of a Randomized Phase 2 Trial in Acute Myeloid Leukemia within the Myelomatch Platform. Blood. American Society of Hematology; 2022. p. 8932–8933.